De Novo Design of Potent and Selective Neuronal Nitric Oxide Synthase (nNOS) Inhibitors by a Fragment-Based Approach

Kemal Yelekci, Bahanur Örtmen


Nitric oxide, a gaseous free radical molecule (NO) behaves, as a secondary messenger in various tissues. It is responsible for different physiological functions and pathological symptoms. Mammals contain three different nitric oxide synthase (NOS) isoforms: neuronal NOS (nNOS: in the brain, in peripheral nervous system and muscle tissues), inducible NOS (iNOS: in macrophage cells), endothelial NOS (eNOS: in endothelial cells). Under certain pathological conditions and/or after certain ages excessive NO produced in brain causes tissue damage and oxidative stress. It also reacts with other free radicals to create specific molecular modifications. The excessive production of NO, especially by nNOS (in brain) is implicated in various disease states such as neurodegeneration, stroke, migraine and Parkinsons, Alzheimers, and Huntingtons diseases. The active sites of three NOS isoforms show great similarity; therefore, designing of selective nNOS inhibitors is not an easy task. The computational results carried out with all of the docking tools clearly demonstrate that the selected scaffold is a potential candidate for further modifications and optimization for designing selective and potent nNOS inhibitors. Subtle differences in the conformations of amino acid sequences (e.g. ASP597 in nNOS) of the three isoforms in the active site region were the determining factors for the selectivity and the potency of the compounds. In this study several hundred compounds were screened in silico using the ZINCv12 lead library for prioritization of lead candidates. De novo design method was used rationally for the modifications of selected scaffold within a target-binding site in order to enhance its binding affinity and selectivity to nNOS enzyme. The potency and the selectivity of nNOS isoform were achieved by introducing 1-methyl amino group at the forth position of the imidazole moiety of the best inhibitor. The positively charged 1-methyl amino group makes three hydrogen bonds with the two-propionate groups of the heme cofactor, which does not occur in eNOS and iNOS. Removing of 1-methyl amino group from scaffold totally abolished both potency and selectivity for nNOS. Newly designed inhibitor 7 shows nNOS inhibition 23 and 17 fold better than both eNOS and iNOS, respectively.


nitric oxide synthase; in silico design; selective nNOS inhibitors; de novo design

Full Text:



Vallance, P.; Leiper, J., Blocking NO synthesis: How, where and why? Nat Rev Drug Discov 2002, 1, 939-50.

Hall, A. V.; Antoniou, H.; Wang, Y.; Cheung, A. H.; Arbus, A. M.; Olson, S. L.; Lu, W. C.; Kau, C. L.; Marsden, P. A., Structural Organization of the Human Neuronal Nitric-Oxide Synthase Gene (Nos1). J Biol Chem 1994, 269, 33082-90.

Montague, P. R.; Gancayco, C. D.; Winn, M. J.; Marchase, R. B.; Friedlander, M. J., Role of No Production in Nmda Receptor-Mediated Neurotransmitter Release in Cerebral-Cortex. Science 1994, 263, 973-7.

Trippier, P. C.; Jansen Labby, K.; Hawker, D. D.; Mataka, J. J.; Silverman, R. B., Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem 2013, 56, 3121-47.

Schmidt, H. H. H. W.; Walter, U., No at Work. Cell 1994, 78, 919-25.

Moncada, S.; Higgs, E. A., The discovery of nitric oxide and its role in vascular biology. Brit J Pharmacol 2006, 147, S193-S201.

Rosen, G. M.; Tsai, P.; Weaver, J.; Porasuphatana, S.; Roman, L. J.; Starkov, A. A.; Fiskum, G.; Pou, S., The role of tetrahydrobiopterin in the regulation of neuronal nitric-oxide synthase-generated superoxide. J Biol Chem 2002, 277, 40275-80.

Zhang, L.; Dawson, V. L.; Dawson, T. M., Role of nitric oxide in Parkinson's disease. Pharmacol Therapeut 2006, 109, 33-41.

Dorheim, M. A.; Tracey, W. R.; Pollock, J. S.; Grammas, P., Nitric-Oxide Synthase Activity Is Elevated in Brain Microvessels in Alzheimers-Disease. Biochem Bioph Res Co 1994, 205, 659-65.

Villanueva, C.; Giulivi, C., Subcellular and cellular locations of nitric oxide synthase isoforms as determinants of health and disease. Free Radical Bio Med 2010, 49, 307-16.

Aquilano, K.; Baldelli, S.; Rotilio, G.; Ciriolo, M. R., Role of Nitric Oxide Synthases in Parkinson's Disease: A Review on the Antioxidant and Anti-inflammatory Activity of Polyphenols. Neurochem Res 2008, 33, 2416-26.

Poulos, T. L.; Li, H. Y., Structural Basis for Isoform-Selective Inhibition in Nitric Oxide Synthase. Accounts Chem Res 2013, 46, 390-8.

Jing, Q.; Li, H.; Chreifi, G.; Roman, L. J.; Martasek, P.; Poulos, T. L.; Silverman, R. B., Chiral linkers to improve selectivity of double-headed neuronal nitric oxide synthase inhibitors. Bioorg Med Chem Lett 2013, 23, 5674-9.

Akdogan, E. D.; Erman, B.; Yelekci, K., In silico design of novel and highly selective lysine-specific histone demethylase inhibitors. Turk J Chem 2011, 35, 523-42.

Oliveira, B. L.; Moreira, I. S.; Fernandes, P. A.; Ramos, M. J.; Santos, I.; Correia, J. D., Insights into the structural determinants for selective inhibition of nitric oxide synthase isoforms. J Mol Model 2013, 19, 1537-51.

Irwin, J. J.; Shoichet, B. K., ZINC - A free database of commercially available compounds for virtual screening. J Chem Inf Model 2005, 45, 177-82.

Raman, C. S.; Li, H.; Martasek, P.; Kral, V.; Masters, B. S. S.; Poulos, T. L., Crystal structure of nitric oxide synthase heme domains. J Inorg Biochem 1999, 74, 44.

Igarashi, J.; Li, H. Y.; Jamal, J.; Ji, H. T.; Fang, J. G.; Lawton, G. R.; Silverman, R. B.; Poulos, T. L., Crystal Structures of Constitutive Nitric Oxide Synthases in Complex with De Novo Designed Inhibitors. J Med Chem 2009, 52, 2060-66.

Li, H. Y.; Raman, C. S.; Glaser, C. B.; Blasko, E.; Young, T. A.; Parkinson, J. F.; Whitlow, M.; Poulos, T. L., Crystal structures of zinc-free and -bound heme domain of human inducible nitric-oxide synthase - Implications for dimer stability and comparison with endothelial nitric-oxide synthase. J Biol Chem 1999, 274, 21276-84.

Yelekci, K.; Buyukturk, B.; Kayrak, N., In silico identification of novel and selective monoamine oxidase B inhibitors. J Neural Transm 2013, 120, 853-858.

Yelekci, K.; Karahan, O.; Toprakci, M., Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties. J Neural Transm 2007, 114, 725-32.

Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J., Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 1998, 19, 1639-62.<1639::AID-JCC10>3.0.CO;2-B

Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S., A semiempirical free energy force field with charge-based desolvation. J Comput Chem 2007, 28, 1145-52.

Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J., AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J Comput Chem 2009, 30, 2785-91.




  • There are currently no refbacks.

Copyright (c)

                              VENSEL PUBLICATIONS@2019

 20, Keelavaithianathapuram, 4th Street, Madurai-625 018 (TN), India